Trulieve's NYSE Listing Is Historic. But Is the Stock Still Worth Buying?

Trulieve became the first U.S. plant-touching cannabis company to list on the NYSE, which should improve access for institutional investors and potentially boost liquidity and analyst coverage. The company remains fundamentally solid, with $1.18 billion in 2025 revenue, $170 million in GAAP gross profit, 59% gross margin, and $42 million in free cash flow in the latest quarter. Still, the article argues the listing alone is not enough to justify buying the stock, given slowing growth, price compression, and a valuation of less than 2x revenue and just over 5x adjusted EBITDA.

Analysis

The NYSE listing is less a fundamental inflection than a distribution upgrade: it should widen the buyer universe, lower implementation friction, and potentially compress the “cannabis discount” embedded by limited access and weak index eligibility. That matters most for marginal flow rather than near-term earnings; if passive/quant screens and larger discretionary funds begin to tolerate the name, the first-order effect is often a valuation rerating before any real operating improvement.

The bigger second-order winner is likely the broader U.S. cannabis ecosystem, not this issuer alone. If one compliant, cash-generative operator can graduate to a major exchange, it reduces reputational and technical barriers for peers, but it also raises the bar: capital will preferentially migrate toward the few operators with clean balance sheets, scale, and positive free cash flow. That should widen dispersion inside the group, with weaker levered names losing relative appeal as investors treat the listing as proof that quality—not sector beta—will drive access to capital.

The main risk is that the market overprices the listing as a catalyst for sustained multiple expansion even though the operating backdrop remains a low-growth, price-competitive category. If revenue stays flat over the next 2-3 quarters, any rerating should be capped unless there is a sharper improvement in margins, debt reduction, or federal/regulatory progress. In that sense, this is more of a liquidity event than a duration event: the best case is a temporary valuation reset, not an immediate re-acceleration of fundamentals.

Contrarian takeaway: the consensus may be underestimating how much of the easy money in cannabis has already been arbitraged away by the most investable names. The listing may help this stock trade more like a mainstream consumer/retail asset, but without top-line inflection the appropriate multiple still looks constrained. The real opportunity may be in fading lower-quality cannabis equities on any sympathy rally and waiting for the stronger operators to become acquisition currency or consolidation winners.

Key Decisions for Investors

• Tactically long TRULIEVE on weakness for 2-6 weeks as a liquidity/visibility trade, but size it as a multiple-expansion trade rather than a fundamentals trade; take profits into any 15-25% move unless EBITDA or FCF guidance improves.
• Short a basket of lower-quality U.S. cannabis operators versus long the most profitable names for 1-3 months; the NYSE listing should widen dispersion as capital concentrates in companies with positive cash generation and manageable leverage.
• Sell upside volatility in TRULIEVE via call spreads if implied vol spikes after the listing headline; the catalyst is more likely to pull forward ownership than to drive a durable re-rating absent a regulatory catalyst.
• If looking for a cleaner expression, pair long TRULIEVE against a weak peer on a 3-6 month horizon to isolate access-to-capital benefits while hedging sector beta and regulatory noise.